Quick Answer
Lineage Cell Therapeutics, Inc. reported Total Revenue of $14.56 million for fiscal year 2025.
Lineage Cell Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $14.56M | +53.2% |
| 2024 | $9.50M | +6.2% |
| 2023 | $8.95M | -39.2% |
| 2022 | $14.70M | +238.7% |
| 2021 | $4.34M | +137.7% |
| 2020 | $1.83M | -47.2% |
| 2017 | $3.46M | -41.6% |
| 2016 | $5.92M | -15.8% |
| 2015 | $7.04M | +34.2% |
| 2014 | $5.24M | +18.3% |
| 2013 | $4.43M | +13.2% |
| 2012 | $3.92M | -11.7% |
| 2011 | $4.43M | +19.6% |
| 2010 | $3.71M | +92.6% |
| 2009 | $1.93M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.68M | -2.6% | +33.1% |
| June 30, 2025 | $2.77M | +96.4% | +84.1% |
| March 31, 2025 | $1.50M | +4.0% | -60.3% |
| September 30, 2024 | $3.78M | +203.3% | +168.4% |
| June 30, 2024 | $1.41M | -56.3% | -2.5% |
| March 31, 2024 | $1.44M | -39.5% | +15.9% |
| September 30, 2023 | $1.25M | -58.4% | -61.4% |
| June 30, 2023 | $3.23M | -29.2% | +35.2% |
- Lineage Cell Therapeutics, Inc. showed an increase of +53.2% in Total Revenue compared to the prior fiscal year.
- Over the 2009–2025 period, Lineage Cell Therapeutics, Inc.’s total revenue has grown by 656.1% (from $1.93 million to $14.56 million).
- The most recent figure is from Lineage Cell Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: